| ANDRE, Thierry |
| Active, not recruiting | 3 | 2000 | Europe | FOLFOX regimen, folinic acid, infusional fluorouracil, and oxaliplatin, CAPOX, capecitabine plus oxaliplatin; XELOX | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer | 01/20 | 12/23 | | |
| Active, not recruiting | 3 | 464 | Europe, RoW | FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche | Colorectal Cancer Metastatic | 07/23 | 12/24 | | |
| Active, not recruiting | 3 | 856 | Europe, RoW | Trifluridine/tipiracil hydrochloride (S95005), Capecitabine, Bevacizumab experimental, Bevacizumab control | Institut de Recherches Internationales Servier, ADIR, a Servier Group company | Metastatic Colorectal Cancer | 06/21 | 06/24 | | |
| Active, not recruiting | 3 | 792 | Europe, Canada | Irinotecan, Campto, Folfox Protocol, acid folinic + oxaliplatine + 5-FU | UNICANCER, Canadian Cancer Trials Group, GONO GROUP | Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) | 06/25 | 06/27 | | |
MOIO, NCT05078047: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO |
|
|
| Recruiting | 3 | 646 | Europe | Reduced dose intensity of IO | UNICANCER | Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Urothelial Carcinoma, Colorectal Carcinoma With Microsatellite Instability, Esophageal Squamous Cell Carcinoma, Endometrial Carcinoma, Cervical Cancer, Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma, Basal Cell Carcinoma, Squamous Skin Carcinoma | 03/25 | 03/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
ImadGist, NCT02260505: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) |
|
|
| Completed | 3 | 136 | Europe | Imatinib maintenance, Glivec, Imatinib mésilate | Centre Leon Berard | Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic, High Risk of Recurrence, KIT Gene Mutation | 12/23 | 12/23 | | |
NIPICOL, NCT03350126: iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab |
|
|
| Active, not recruiting | 2 | 57 | Europe | Ipilimumab 200 MG in 40 ML Injection, Nivolumab 10 MG/ML | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Metastatic Cancer Colorectal | 02/19 | 12/23 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
NEONIPIGA, NCT04006262: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. |
|
|
| Recruiting | 2 | 32 | Europe | Nivolumab 10 MG/ML, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Localized Oesogastric Adenocarcimona, MSI and or dMMR | 06/24 | 06/24 | | |
|
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI |
|
|
| Recruiting | 2 | 120 | Europe | Dostarlimab, Chemotherapy | UNICANCER, National Cancer Institute, France, GlaxoSmithKline | Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma | 10/28 | 09/30 | | |
DEWI, NCT06059495: Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study |
|
|
| Recruiting | 2 | 59 | Europe | Dostarlimab, Jemperli | GERCOR - Multidisciplinary Oncology Cooperative Group | Adenocarcinoma - GEJ, Gastric Adenocarcinoma | 09/28 | 09/28 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 740 | Europe, Canada, US, RoW | Dostarlimab | Tesaro, Inc. | Neoplasms | 05/26 | 10/27 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
| MINEUR, Laurent |
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over |
|
|
| Recruiting | 3 | 774 | Europe | LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine | Federation Francophone de Cancerologie Digestive | Colonic Adenocarcinoma | 12/24 | 08/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
|
|
| Recruiting | 3 | 348 | Europe | Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 09/25 | 09/27 | | |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
| Active, not recruiting | 2 | 99 | Europe | MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG | Anal Cancer | 02/23 | 12/24 | | |
OESIRI, NCT03719924: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 106 | Europe | Onivyde, no other intervention name to add, Paclitaxel | Federation Francophone de Cancerologie Digestive, Shire | Squamous Cell Carcinoma | 11/24 | 04/25 | | |
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
|
|
| Active, not recruiting | 2 | 55 | Europe | Blood sample collection, Biopsy | Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim | Squamous Cell Carcinoma of the Anus Stage III | 07/24 | 07/26 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
| Active, not recruiting | 2 | 219 | Europe | Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan | UNICANCER | Metastatic Colorectal Cancer | 12/24 | 01/25 | | |
TASKIN, NCT05201352: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine |
|
|
| Recruiting | 1/2 | 160 | Europe | trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo | Centre Georges Francois Leclerc | Metastatic Colorectal Cancer | 10/26 | 10/26 | | |
IMMUNOREC, NCT06536127: Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer |
|
|
| Recruiting | N/A | 100 | Europe | Blood samples | Institut Sainte Catherine | Rectal Cancer, Non Metastatic Cancer | 07/26 | 07/28 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
| Hegewisch-Becker, Susanna |
| Completed | N/A | 2325 | Europe | | iOMEDICO AG | Pancreas Cancer | 04/22 | 06/24 | | |
| TOUCHEFEU, Yann |
RePERSO, NCT04874207: Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients with Metastatic Colorectal Cancer Treated with REgorafenib |
|
|
| Active, not recruiting | 4 | 110 | Europe | Regorafenib | Rennes University Hospital | Colorectal Cancer Metastatic | 06/25 | 12/25 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
|
|
| Recruiting | 3 | 348 | Europe | Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 09/25 | 09/27 | | |
| Recruiting | 3 | 800 | Europe | Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament | Biliary Tract Neoplasms | 06/27 | 06/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Recruiting | 2 | 100 | Europe, US | TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 06/27 | 06/27 | | |
TASKIN, NCT05201352: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine |
|
|
| Recruiting | 1/2 | 160 | Europe | trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo | Centre Georges Francois Leclerc | Metastatic Colorectal Cancer | 10/26 | 10/26 | | |
| Recruiting | N/A | 325 | Europe | Semi-directed individual interviews, The self-administered questionnaires, rPATD and BMQ, The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale) | Nantes University Hospital, Fondation de France, Nantes Université | Deprescribing, Palliative Care, Oncology | 02/25 | 12/26 | | |
OPERANDI-HCC, NCT06334965: Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort |
|
|
| Not yet recruiting | N/A | 180 | Europe | Simultaneous 18F-Choline PET-MRI | Assistance Publique - Hôpitaux de Paris | Hepatocellular Carcinoma, Radioembolization | 11/27 | 09/29 | | |
OPERANDI-NET, NCT06256705: Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort |
|
|
| Recruiting | N/A | 80 | Europe | Simultaneous 68Ga-DOTATOC PET-MRI | Assistance Publique - Hôpitaux de Paris | Gastroenteropancreatic Neuroendocrine Tumor, Radiotherapy | 03/28 | 09/29 | | |
PROPERTY, NCT05025826: Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy |
|
|
| Recruiting | N/A | 110 | Europe | Phycocare, Placebo | Nantes University Hospital, Algosource | Metastatic Gastric Cancer | 08/25 | 03/26 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study |
|
|
| Recruiting | N/A | 1350 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Biliary Tract Cancer | 06/30 | 06/40 | | |
| Forestier, Julien |
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over |
|
|
| Recruiting | 3 | 774 | Europe | LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine | Federation Francophone de Cancerologie Digestive | Colonic Adenocarcinoma | 12/24 | 08/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
|
|
| Recruiting | 3 | 348 | Europe | Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 09/25 | 09/27 | | |
| Recruiting | 2 | 60 | Europe | Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab | Hospices Civils de Lyon | Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma | 10/23 | 10/23 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
PROFILER, NCT01774409: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer |
|
|
| Recruiting | N/A | 10000 | Europe | Blood and tumor samples | Centre Leon Berard | Neoplasms | 07/25 | 07/26 | | |
| APARICIO, Thomas |
| Active, not recruiting | 3 | 792 | Europe | Geriatrician Intervention | Institut Bergonié, Ministry of Health, France | Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer, Ovarian Cancer, Lymphoma | 12/23 | 03/26 | | |
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over |
|
|
| Recruiting | 3 | 774 | Europe | LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine | Federation Francophone de Cancerologie Digestive | Colonic Adenocarcinoma | 12/24 | 08/25 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
|
|
| Recruiting | 3 | 348 | Europe | Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 09/25 | 09/27 | | |
| Completed | 2 | 77 | Europe | DONEPEZIL, PLACEBO | University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive | Digestive Oncology, Supportive Care | 01/24 | 01/24 | | |
| Recruiting | 2 | 60 | Europe | Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab | Hospices Civils de Lyon | Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma | 10/23 | 10/23 | | |
| Active, not recruiting | 2 | 240 | Europe | Pembrolizumab, MK3475 - Keytruda® | Centre Leon Berard | Localized Resectable Tumor, MSI/dMMR | 11/25 | 10/29 | | |
OESIRI, NCT03719924: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 106 | Europe | Onivyde, no other intervention name to add, Paclitaxel | Federation Francophone de Cancerologie Digestive, Shire | Squamous Cell Carcinoma | 11/24 | 04/25 | | |
NEONIPIGA, NCT04006262: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. |
|
|
| Recruiting | 2 | 32 | Europe | Nivolumab 10 MG/ML, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Localized Oesogastric Adenocarcimona, MSI and or dMMR | 06/24 | 06/24 | | |
|
BIG, NCT06253611: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 120 | Europe | Nivolumab, Opdivo, FOLFOX regimen, Leucovorin, fluorouracil, and oxaliplatin, EXL01 | GERCOR - Multidisciplinary Oncology Cooperative Group | Gastric Cancer | 03/26 | 03/29 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
LOGICAN, NCT05476796: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer |
|
|
| Recruiting | 2 | 118 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO | UNICANCER, Servier | Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 01/26 | 01/27 | | |
| Recruiting | N/A | 402 | Europe | treatment for ampullary adenocarcinoma, no other intervention name to add | Federation Francophone de Cancerologie Digestive | Ampullary Adenocarcinoma | 12/22 | 12/22 | | |
| Not yet recruiting | N/A | 500 | Europe | Sampling | Assistance Publique - Hôpitaux de Paris | Colon Cancer, Peritoneal Carcinoma | 06/25 | 06/39 | | |
| Recruiting | N/A | 103 | Europe | Blood Sample Collection | Jules Bordet Institute, Hoffmann-La Roche | Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Candidate for Third-line or Subsequent Lines of Therapy | 01/26 | 07/26 | | |
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 400 | Europe | Collection of blood samples | UNICANCER, Pierre Fabre Medicament | Metastatic Colorectal Cancer, BRAF V600E Mutation Positive | 07/27 | 07/28 | | |
| Not yet recruiting | N/A | 222 | Europe | PET/CT | Assistance Publique - Hôpitaux de Paris | Metastatic Colorectal Cancer | 01/25 | 09/27 | | |
